Announced Fri, 31 Oct · 13:00 IST
Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 31, 2025, titled "Strides Delivers a Robust Q2FY26 with Highest Ever Quarterly EPSQ2FY26 Operational PAT at ₹1,403m and EPS at ₹15.2, Grew 84% YoY".
Compliance View source PDF
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve
Awaiting price reaction for this filing.
AI summary
Strides Pharma Science reported a strong Q2FY26 performance with operational profit after tax (PAT) of ₹1,403 million. The company posted earnings per share (EPS) of ₹15.2, growing 84% year-on-year. This marks the highest ever quarterly EPS in the company's history. The headline 'Robust Q2FY26' suggests broad-based strength in operations during the quarter ending September 2025.
Likely market impact
Strong Q2 results with record-high EPS and 84% YoY growth signal solid operational momentum, which is likely positive for shareholder sentiment and the stock price in the near term.